Daniel Brennan
Stock Analyst at TD Cowen
(2.72)
# 1,984
Out of 4,711 analysts
20
Total ratings
53.33%
Success rate
20.1%
Average return
Main Sectors:
Stocks Rated by Daniel Brennan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTRX Quanterix | Maintains: Hold | $14 → $16 | $10.50 | +52.38% | 2 | Nov 13, 2024 | |
| LAB Standard BioTools | Maintains: Buy | $2.75 → $2.5 | $2.00 | +25.00% | 3 | Oct 31, 2024 | |
| AVTR Avantor | Maintains: Buy | $30 → $29 | $21.21 | +36.73% | 5 | Oct 8, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $12 → $2.5 | $1.97 | +26.90% | 2 | Apr 17, 2024 | |
| TMO Thermo Fisher | Maintains: Overweight | $613 → $670 | $524.05 | +27.85% | 1 | Feb 2, 2023 | |
| CRL Charles River Laboratories International | Upgrades: Buy | $177 → $200 | $185.77 | +7.66% | 2 | May 13, 2020 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $755 → $770 | $1,230.74 | -37.44% | 2 | May 8, 2020 | |
| EXAS Exact Sciences | Maintains: Buy | $135 → $115 | $59.40 | +93.60% | 3 | Apr 28, 2020 |
Quanterix
Nov 13, 2024
Maintains: Hold
Price Target: $14 → $16
Current: $10.50
Upside: +52.38%
Standard BioTools
Oct 31, 2024
Maintains: Buy
Price Target: $2.75 → $2.5
Current: $2.00
Upside: +25.00%
Avantor
Oct 8, 2024
Maintains: Buy
Price Target: $30 → $29
Current: $21.21
Upside: +36.73%
Pacific Biosciences of California
Apr 17, 2024
Maintains: Buy
Price Target: $12 → $2.5
Current: $1.97
Upside: +26.90%
Thermo Fisher
Feb 2, 2023
Maintains: Overweight
Price Target: $613 → $670
Current: $524.05
Upside: +27.85%
Charles River Laboratories International
May 13, 2020
Upgrades: Buy
Price Target: $177 → $200
Current: $185.77
Upside: +7.66%
Mettler-Toledo International
May 8, 2020
Maintains: Neutral
Price Target: $755 → $770
Current: $1,230.74
Upside: -37.44%
Exact Sciences
Apr 28, 2020
Maintains: Buy
Price Target: $135 → $115
Current: $59.40
Upside: +93.60%